Drug intelligence / Profile preview

S247567

Development stage: Preclinical
Lead developer: Servier

Overview

S247567 is an investigational drug candidate currently in preclinical development by Servier and its subsidiary Symphogen. It is being evaluated for the treatment of hematological malignancies. As of early 2026, the specific molecular target and therapeutic modality (such as small molecule or monoclonal antibody) remain undisclosed by the developers. The program is part of Servier's oncology pipeline focused on addressing unmet needs in blood-based cancers.

Beyond the preview

Go deeper on S247567.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on S247567.

Explore the full profile